Actuate Therapeutics (ACTU) plans to raise $50 million in an initial public offering on the week of June 24th,...
Read more
Actuate Therapeutics plans to sell nearly 5.56 million shares at between $8 and $10 apiece in its initial public...
Read more
Actuate Therapeutics, a Phase 2 biotech developing in-licensed inhibitor therapies for difficult to treat cancers, filed on Friday with...
Read more
Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib...
Read more
Tempus announced a brand-new multi-omics collaboration with Actuate Therapeutics to support its ongoing Phase 1/2 Study of elraglusib, formerly...
Read more
Actuate Therapeutics and The University of Kansas Cancer Center announced the enrollment of the first patient on a Phase...
Read more
Actuate Therapeutics, Inc. announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met...
Read more
Actuate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for...
Read more
Actuate Therapeutics, Inc. announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study...
Read more
Actuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with...
Read more